Drug Target Review

JULY 13, 2023

In recent years, a novel approach known as condensate biology has emerged, revolutionising the way researchers think about drug discovery and development. Dewpoint Therapeutics, a platform drug discovery company founded in 2018, has been at the forefront of this exciting field.

Disease 98

Disease Small Molecule Cell Biology Drugs 98

The Pharma Data

DECEMBER 1, 2020

Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia.

Cell Biology 52

Cell Biology Clinical Trials Production Licensing 52

The Pharma Data

OCTOBER 22, 2020

Monalizumab may re-establish a broad anti-tumor response mediated by NK and T cells, and may enhance the cytotoxic potential of other therapeutic antibodies (André et al, Cell 2018). Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia.

Clinical Trials 40

Clinical Trials Trials Cell Biology Production 40

Codon

SEPTEMBER 22, 2024

Activated follicles will mature into antral follicles, consisting of a fully grown oocyte surrounded by several layers of different types of ovarian somatic cells. In 2018, Saitou’s team reported the first method to coax human PGC-like cells into the oogonia stage. Then, I induce the signaling pathways involved in meiosis.

DNA 112

DNA Laboratories Regulations Therapies 112

Codon

AUGUST 10, 2023

Credit: Bruce Wetzel and Harry Schaefer, NCI, NIH | License Progress in biology is arguably moving faster today than at any point in the course of human history. Engineered biology has profound potential to change how we live, but the field has become broad, bloated, nebulous. Nature Reviews Molecular Cell Biology (2009).

DNA 98

DNA Cell Biology Molecular Biology Engineering 98

Codon

AUGUST 10, 2023

Credit: Bruce Wetzel and Harry Schaefer, NCI, NIH | License Last edit: 13 September 2023 Progress in biology is arguably moving faster today than at any point in the course of human history. Engineered biology has profound potential to change how we live, but the field has become broad, bloated, nebulous. Artificial Life (2018).

DNA 52

DNA Cell Biology Engineering Molecular Biology 52

Drug Target Review

MARCH 26, 2025

Lisa is a fellow in the American Institute of Medical and Biological Engineering. She has a background in cell biology, biophysics and pharmacology and was a professor and Chair at the University of Kansas for over 20 years.

Therapies 52

Therapies Compliance Treatment Small Molecule 52